Q1 Earnings Forecast for RARE Issued By Leerink Partnrs

Key Points

• Leerink Partners predicts Ultragenyx Pharmaceutical will report Q1 2026 earnings per share of ($1.30), with full-year estimates reaching ($5.18) per share.
• Ultragenyx shares received various price targets from analysts, including a drop from $112.00 to $105.00 by Cantor Fitzgerald, while HC Wainwright raised it to $80.00, showcasing a mixed market outlook.
• Institutional investors now own 97.67% of Ultragenyx Pharmaceutical's stock, indicating strong institutional confidence in the company's future despite recent earnings challenges.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2026 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a note issued to investors on Tuesday, August 5th. Leerink Partnrs analyst J. Schwartz anticipates that the biopharmaceutical company will post earnings of ($1.30) per share for the quarter. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. Leerink Partnrs also issued estimates for Ultragenyx Pharmaceutical's Q2 2026 earnings at ($1.12) EPS, Q3 2026 earnings at ($1.21) EPS, Q4 2026 earnings at ($0.95) EPS and FY2027 earnings at $0.42 EPS.

Other research analysts have also recently issued reports about the company. Wells Fargo & Company decreased their price target on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research note on Thursday, July 10th. Cantor Fitzgerald cut their price objective on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 6th. HC Wainwright raised Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 target price on the stock in a report on Monday, July 28th. Canaccord Genuity Group decreased their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research note on Friday. Finally, Guggenheim restated a "buy" rating and issued a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $81.50.

Ultragenyx Pharmaceutical Stock Down 1.4%

NASDAQ:RARE traded down $0.39 during trading hours on Thursday, reaching $27.15. 571,879 shares of the stock were exchanged, compared to its average volume of 1,287,806. The business has a 50-day moving average of $33.32 and a two-hundred day moving average of $36.68. Ultragenyx Pharmaceutical has a twelve month low of $25.81 and a twelve month high of $60.37. The company has a market capitalization of $2.62 billion, a price-to-earnings ratio of -4.91 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%. The company had revenue of $166.50 million during the quarter, compared to analyst estimates of $161.37 million. During the same period in the previous year, the business earned ($1.52) EPS. Ultragenyx Pharmaceutical's quarterly revenue was up 13.2% on a year-over-year basis.

Insider Activity

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the stock in a transaction on Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the sale, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. This represents a 13.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 5.50% of the company's stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 1,061.9% in the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 669 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at about $35,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Ultragenyx Pharmaceutical in the first quarter valued at about $57,000. Finally, Headlands Technologies LLC bought a new stake in Ultragenyx Pharmaceutical during the first quarter worth about $59,000. Institutional investors and hedge funds own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.